Literature DB >> 26323069

Halting renal fibrosis: an unexpected role for mTORC2 signaling.

Florian Grahammer1.   

Abstract

Slowly progressive renal fibrosis is the hallmark of chronic kidney disease, independent of its etiology. Transforming growth factor-β (TGF-β) has been found to be the main profibrotic renal cytokine. Li et al. identify mTORC2 as an important mediator of TGF-β signaling. Being upstream of the previously described profibrotic kinases AKT, SGK1, and PKC-α, mTORC2 represents a potentially interesting drug target. Yet, although the mouse genetic approach yielded convincing results, transition from bench to bedside will remain challenging.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26323069     DOI: 10.1038/ki.2015.137

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 2.  Mechanisms of tubulointerstitial fibrosis.

Authors:  Michael Zeisberg; Eric G Neilson
Journal:  J Am Soc Nephrol       Date:  2010-09-23       Impact factor: 10.121

3.  An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.

Authors:  Kameswaran Ravichandran; Iram Zafar; Abdullah Ozkok; Charles L Edelstein
Journal:  Nephrol Dial Transplant       Date:  2014-09-19       Impact factor: 5.992

4.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

5.  Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity.

Authors:  Monique E Cho; John K Hurley; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

6.  Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Authors:  Klemens Budde; Thomas Becker; Wolfgang Arns; Claudia Sommerer; Petra Reinke; Ute Eisenberger; Stefan Kramer; Wolfgang Fischer; Harald Gschaidmeier; Frank Pietruck
Journal:  Lancet       Date:  2011-02-19       Impact factor: 79.321

7.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  John J Bissler; J Christopher Kingswood; Elżbieta Radzikowska; Bernard A Zonnenberg; Michael Frost; Elena Belousova; Matthias Sauter; Norio Nonomura; Susanne Brakemeier; Petrus J de Vries; Vicky H Whittemore; David Chen; Tarek Sahmoud; Gaurav Shah; Jeremie Lincy; David Lebwohl; Klemens Budde
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

8.  Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis.

Authors:  Lei Jiang; Lingling Xu; Junhua Mao; Jianzhong Li; Li Fang; Yang Zhou; Wei Liu; Weichun He; Allan Zijian Zhao; Junwei Yang; Chunsun Dai
Journal:  J Am Soc Nephrol       Date:  2013-05-09       Impact factor: 10.121

9.  Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis.

Authors:  Jianzhong Li; Jiafa Ren; Xin Liu; Lei Jiang; Weichun He; Weiping Yuan; Junwei Yang; Chunsun Dai
Journal:  Kidney Int       Date:  2015-05-13       Impact factor: 10.612

  9 in total
  4 in total

Review 1.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

Review 2.  Signalling pathways involved in hypoxia-induced renal fibrosis.

Authors:  Minna Liu; Xiaoxuan Ning; Rong Li; Zhen Yang; Xiaoxia Yang; Shiren Sun; Qi Qian
Journal:  J Cell Mol Med       Date:  2017-01-18       Impact factor: 5.310

Review 3.  Deciphering the SUMO code in the kidney.

Authors:  Zhen Yang; Yuming Zhang; Shiren Sun
Journal:  J Cell Mol Med       Date:  2018-12-01       Impact factor: 5.310

Review 4.  Serum and Glucocorticoid Regulated Kinase 1 in Sodium Homeostasis.

Authors:  Yiyun Lou; Fan Zhang; Yuqin Luo; Liya Wang; Shisi Huang; Fan Jin
Journal:  Int J Mol Sci       Date:  2016-08-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.